Healthcare Services

Global congenital heart disease market to reach $7.27B by 2030 at 8.1% CAGR

April 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Congenital Heart Disease (CHD) Market Grow Between 2026 And 2030?

The market size for congenital heart disease (chd) has demonstrated robust growth over recent years. It is forecast to increase from $4.85 billion in 2025 to $5.32 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.7%. This historical expansion can be linked to factors such as the high prevalence of structural birth defects, limited early diagnostic capabilities, a reliance on open-heart surgery, high infant mortality rates, and the concentration of care in tertiary hospitals.

The congenital heart disease (chd) market size is anticipated to undergo significant expansion in the upcoming years. It is projected to climb to $7.27 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.1%. The expansion over this forecast period stems from various factors, including advancements in minimally invasive cardiology, enhancements in imaging and diagnostics, the expanding adult chd population, the proliferation of specialized cardiac centers, and escalating healthcare investments. Noteworthy trends during the forecast period involve an increase in early prenatal and neonatal screening, a rising acceptance of catheter-based interventions, the broadening of pediatric and adult chd care programs, improved survival rates prompting more adult chd care, and a focus on multidisciplinary long-term disease management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Which Drivers Are Supporting The Congenital Heart Disease (CHD) Market Growth?

The increasing incidence of maternal diabetes cases is anticipated to fuel the expansion of the congenital heart disease (CHD) market. Maternal diabetes, also known as gestational diabetes mellitus (GDM), is a condition where diabetes develops during pregnancy in women who were not diabetic before conceiving. This condition often stems from lifestyle modifications, such as sedentary habits and poor dietary choices, coupled with a general rise in obesity rates among women of childbearing age. Maternal diabetes can lead to congenital heart disease (CHD) in infants because elevated blood sugar levels negatively impact fetal heart development. The heightened glucose concentrations in the mother’s bloodstream can disrupt the proper formation of the baby’s heart, thereby increasing the likelihood of CHD. For instance, a report from November 2025 by the Society For Maternal Fetal Medicine, a US-based organisation, indicates that gestational diabetes mellitus (GDM) affects approximately 15.6% of women globally, with an estimated 23.3 million live births impacted by hyperglycemia during pregnancy in 2024. Consequently, the rising number of maternal diabetes cases is a significant factor driving the growth of the congenital heart disease (CHD) market.

What Are The Different Segment Types In The Congenital Heart Disease (CHD) Market Segment Breakdown?

The congenital heart disease (chd) market covered in this report is segmented –

1) By Type: Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, Other Types

2) By Diagnosis: Electrocardiogram, Chest X-ray, Echocardiogram, Transesophageal Echocardiogram, Pulse Oximetry, Exercise Stress Test, Cardiac Computed Tomography (CT) Scan Or Magnetic Resonance Imaging (MRI), Cardiac Catheterization, Other Diagnosis

3) By Treatment: Interventional Cardiology, Cardiac Surgery, Telemedicine, Medication Management, Lifestyle Modifications

4) By Age Group: Infants, Children, Adolescents, Adults

5) By Application: Hospitals And Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Research And Academic Institutions

Subsegments:

1) By Heart Valve Defects: Aortic Valve Stenosis, Pulmonary Valve Stenosis, Mitral Valve Prolapse, Tricuspid Valve Defects, Valve Regurgitation

2) By Heart Wall Defects: Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), Atrioventricular Septal Defect (AVSD), Hypoplastic Left Heart Syndrome (HLHS), Tetralogy of Fallot (TOF)

3) By Blood Vessel Defects: Coarctation Of The Aorta, Patent Ductus Arteriosus (PDA), Pulmonary Artery Stenosis, Transposition Of The Great Arteries (TGA), Truncus Arteriosus

4) By Other Types: Single Ventricle Defects, Ebstein’s Anomaly, Total Anomalous Pulmonary Venous Return (TAPVR), Coronary Artery Anomalies, Pulmonary Venous Obstruction

Which Trends Are Expected To Impact The Congenital Heart Disease (CHD) Market?

Key companies operating in the congenital heart disease market are developing non-surgical heart valves, aiming to improve patient outcomes and their quality of life. These non-surgical, or transcatheter, medical devices address heart valve conditions without the necessity of traditional open-heart surgery. For instance, in February 2023, Medtronic, a US-based medical technology company, reintroduced its Harmony Transcatheter Pulmonary Valve (TPV) System. This system presents a groundbreaking, minimally invasive option for patients with congenital heart disease, particularly those with native or surgically repaired right ventricular outflow tract (RVOT) anomalies, as an alternative to open-heart surgery. It is the first FDA-approved valve specifically designed for the right side of the heart, offering a non-surgical solution for individuals suffering from severe pulmonary valve regurgitation. The Harmony TPV System originally received U.S. FDA approval in 2021 and was reintroduced following a voluntary recall, thereby demonstrating Medtronic’s commitment to advancing solutions for congenital heart disease patients.

Who Are The Well-Known Companies In The Congenital Heart Disease (CHD) Market?

Major companies operating in the congenital heart disease (chd) market are Abbott Laboratories, Medtronic, Siemens Healthineers, Philips Healthcare, Roche Diagnostics International Ltd., Boston Scientific Corp., Laboratory Corporation of America Holdings (LabCorp), Terumo Corporation, Mindray Medical International Limited, Canon Medical Systems Corporation, Masimo Corporation, Carestream Health, Schiller AG, BPL Medical Technologies, Bionet America Inc., Edwards Lifesciences Corporation, GE Healthcare, BIOTRONIK SE & Co KG, W L Gore & Associates Inc, Cook Medical, Lepu Medical Technology Co Ltd, Getinge AB, Merit Medical Systems Inc, Eurocor Tech GmbH, Braile Biomedica

Get The Full Congenital Heart Disease (CHD) Market Report:

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Where Is The Congenital Heart Disease (CHD) Market Most Concentrated Geographically?

North America was the largest region in the congenital heart disease (CHD) market in 2025. The regions covered in the congenital heart disease (chd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Congenital Heart Disease (CHD) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Browse Through More Reports Similar to the Global Congenital Heart Disease (CHD) Market 2026, By The Business Research Company

Pediatric Heart Valve Repair And Replacement Market Report 2026

https://www.thebusinessresearchcompany.com/report/pediatric-heart-valve-repair-and-replacement-global-market-report

Congenital Heart Defect Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/congenital-heart-defect-devices-global-market-report

Cardiometabolic Diseases Market Report 2026

https://www.thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795